These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 18712130)

  • 1. [Treatment of chronic osteoarthritis pain: effectivity and safety of a 7 day matrix patch with a low dose buprenorphine].
    Schutter U; Ritzdorf I; Heckes B
    MMW Fortschr Med; 2008 Jun; 150 Suppl 2():96-103. PubMed ID: 18712130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain.
    James IG; O'Brien CM; McDonald CJ
    J Pain Symptom Manage; 2010 Aug; 40(2):266-78. PubMed ID: 20541900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The transdermal 7-day buprenorphine patch--an effective and safe treatment option, if tramadol or tilidate/naloxone is insufficient. Results of a non-interventional study].
    Schutter U; Ritzdorf I; Heckes B
    MMW Fortschr Med; 2010 Jul; 152 Suppl 2():62-9. PubMed ID: 21591321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
    Likar R; Kayser H; Sittl R
    Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study.
    Karlsson M; Berggren AC
    Clin Ther; 2009 Mar; 31(3):503-13. PubMed ID: 19393841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Post marketing surveillance study with an analgesic (transdermal buprenorphine patch) in patients with moderate to severe chronic pain].
    Tschirner M; Ritzdorf I; Brünjes R
    MMW Fortschr Med; 2008 Sep; 150 Suppl 3():142-8. PubMed ID: 19025217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Application of a seven-day buprenorphine transdermal patch in multimorbid patients on long-term ibuprofen or diclofenac].
    Böhme K; Heckes B; Thomitzek K
    MMW Fortschr Med; 2011 Jan; 152 Suppl 4():125-32. PubMed ID: 21598463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients.
    Griessinger N; Sittl R; Likar R
    Curr Med Res Opin; 2005 Aug; 21(8):1147-56. PubMed ID: 16083522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
    Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I
    Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal buprenorphine in the treatment of chronic pain.
    Sittl R
    Expert Rev Neurother; 2005 May; 5(3):315-23. PubMed ID: 15938664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study.
    Mercadante S; Porzio G; Ferrera P; Aielli F; Verna L; Tirelli W; Villari P; Casuccio A
    Clin Ther; 2009 Oct; 31(10):2134-8. PubMed ID: 19922884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High dose transdermal buprenorphine for moderate to severe pain in spanish pain centres--a retrospective multicenter safety and efficacy study.
    Barutell C; Camba A; González-Escalada JR; Rodríguez M;
    Pain Pract; 2008; 8(5):355-61. PubMed ID: 18662364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients.
    Freye E; Anderson-Hillemacher A; Ritzdorf I; Levy JV
    Pain Pract; 2007 Jun; 7(2):123-9. PubMed ID: 17559481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age.
    Likar R; Vadlau EM; Breschan C; Kager I; Korak-Leiter M; Ziervogel G
    Clin J Pain; 2008; 24(6):536-43. PubMed ID: 18574363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain.
    Poulain P; Denier W; Douma J; Hoerauf K; Samija M; Sopata M; Wolfram G
    J Pain Symptom Manage; 2008 Aug; 36(2):117-25. PubMed ID: 18411010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transdermal buprenorphine in pain management--experiences from clinical practice: Five case studies.
    Louis F
    Int J Clin Pract; 2006 Oct; 60(10):1330-4. PubMed ID: 16981980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal buprenorphine plus oral paracetamol vs an oral codeine-paracetamol combination for osteoarthritis of hip and/or knee: a randomised trial.
    Conaghan PG; O'Brien CM; Wilson M; Schofield JP
    Osteoarthritis Cartilage; 2011 Aug; 19(8):930-8. PubMed ID: 21477658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine TDS: use in daily practice, benefits for patients.
    Radbruch L
    Int J Clin Pract Suppl; 2003 Feb; (133):19-22; discussion 23-4. PubMed ID: 12665120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.